AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01431339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin/Linezolid
Description: IV Vancomycin (1 gram Q 12 hours or 15mg/Kg Q 12 hours) with optional switch to oral linezolid (600 mg every 12 hours). Total duration of therapy is 10-14 days
Study NCT03462784 — intervention group
Intervention type: OTHER
Intervention: Demographic, physical examination, data will becollected .
Description: Demographic data collected includ clinical diagnosis, sex, race, genotype, and phenotype.~Historical data included information regarding immunizations, infection exposures, surgical procedures, organ dysfunction(Organ dysfunction was defined as a history of requiring medical treatment for heart disease, diabetes (Type 1 or 2), hypoparathyroidism, hypothyroidism, growth hormone deficiency, or gonadal failure) age at transfusion initiation, chelation therapy, type of RBC product, transfusion reactions, and antigen matching. Data will be collected from chart review, patient interviews, blood banking records, and laboratory
Study NCT04405323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AG06466
Description: hard capsules, orally, single doses
Study NCT04405323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: 200 and 300 mg, capsules, orally
Study NCT00800111 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: endothelial keratoplasty
Description: Endothelial keratoplasty is surgical replacement of the corneal endothelial cell layer (the cell layer lining the inner surface of the cornea).
Study NCT03782714 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Description: It is a diode laser device that has laser set at low level, used for pain relief and inflammation reduction to induce healing
Study NCT03848039 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gardasil-9
Description: administration by intramuscular injection of the 9-valent HPV vaccine according to a 3-dose vaccination schedule (0, 2, 6 months).
Study NCT03848039 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administration by intramuscular injection of the placebo according to vaccination schedule of the 9-valent HPV vaccine (0, 2, 6 months)
Study NCT02560753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T3D-959
Description: The 3mg dosage is supplied as 1mg capsules (three capsules, taken once daily by mouth) The 10mg dosage is supplied as 5mg capsules (two capsules, taken once daily by mouth) The 30mg dosage is supplied as either 5mg or 15mg capsules (six 5mg capsules or two 15mg capsules taken once daily by mouth) The 90mg dosage is supplied as 15mg capsules (six capsules, taken once daily by mouth)
Study NCT03063944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STAT Inhibitor OPB-111077
Description: Given PO
Study NCT03063944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV
Study NCT03063944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT03063944 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03987971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Acupuncture on GB26, every other day, 3 times a week, 2 weeks in total.
Study NCT03987971 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: acupuncture
Description: Acupuncture on GB26, every other day, 3 times a week, 2 weeks in total.
Study NCT01227291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYL040012
Description: SYL040012 ophthalmic drops, daily single dose administration
Study NCT04012619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride
Description: Patients receive pemetrexed with cisplatin/carboplatin once every 3 weeks, and anlotinib (dose escalation) once daily on days 1-14.
Study NCT03689634 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Move For Surgery Preconditioning Program using a Wearable Activity Tracker (Fitbit) Intervention Group
Description: Participants randomized to this group will be be provided with a wearable activity tracker (Fitbit) for the duration of the study and asked to reach daily step goals.
Study NCT02896075 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 30 Minute Comedy Video
Description: The intervention is a 30 minute video of a comedy
Study NCT02896075 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 30 Minute Documentary Video
Description: The intervention is a 30 minute video of an uninteresting documentary
Study NCT01973153 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Motivational Counseling (BMC)
Description: 3-5 minute BMC delivered by clinicians and nurses at well, sick, and WIC visits with the goal of reducing obesogenic behaviors. During BMC, the medical team facilitates the selection of a specific goal (i.e., reduce sugar sweetened beverage consumption) that is meaningful to the mother and teaches the mother simple behavioral strategies.
Study NCT01973153 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Motivational Counseling Plus Phone Calls (BMC + Phone)
Description: BMC as described above that is supplemented by monthly telephone contacts with community health workers designed to identify and overcome barriers to goal progress.
Study NCT01973153 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Motivational Counseling Plus Home Visits (BMC + Home)
Description: BMC as described above that is supplemented by monthly home visits with community health workers designed to identify and overcome barriers to goal progress.
Study NCT03408405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acthar Gel 80 UNT/ML Injectable Solution
Description: Participant will self inject 'Acthar Gel 80 UNT/ML Injectable Solution' 2 x per week for six months.
Study NCT02702778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Delayed-Release (DR) Prednisone
Description: delayed release prednisone
Study NCT02702778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Release (IR) Prednisone
Description: standard prednisone
Study NCT02783573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanabecestat
Description: Administered orally
Study NCT02783573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally
Study NCT01145989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT9283
Description: Starting dose will be 40 mg/m2/day OR 30 mg/m2/day to be confirmed at registration. IV 24 hour continuous infusion Days 1 and 8 every three weeks
Study NCT02517177 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Parabolic flight
Study NCT02517177 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cardiovascular parameters measurements
Study NCT02611453 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Air contrast cholangiography using carbon dioxide gas
Description: Carbon dioxide (CO2) will be injected into the biliary tree (which is already exposed to CO2 during routine ERCP) and images will be obtained by using fluoroscopy and digital subtraction imaging (a specific setting on certain fluoroscopy tables).
Study NCT02986191 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mucograft
Description: This method of grafting will be used to treat the gingival recession using coronally advanced flaps.
Study NCT02986191 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Connective Tissue Graft
Description: This will be used in the traditional manner to correct gingival recession
Study NCT00821262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevoflurane
Study NCT00821262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Study NCT01681277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 113608 PIB bid
Description: powder for oral solution
Study NCT01681277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to BI 113608 PIB bid
Description: powder for oral solution
Study NCT01681277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to BI 113608 PIB qd
Description: powder for oral solution
Study NCT01681277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 113608 PIB qd
Description: powder for oral solution
Study NCT01200342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genasense
Description: 900 mg by vein over 1 hour on Days 1, 3, and 5 of a 21 day cycle.
Study NCT01200342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m\^2 by vein over 3 hours on Day 3 of a 21 day cycle following Genasense.
Study NCT01200342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin starting dose in mg (AUC= 6) is administered over 30 minutes IV Piggyback (IVPB). Carboplatin will be dosed after Paclitaxel dose on Day 3 every 3 weeks.~The total dose of Carboplatin is calculated using a formula based upon a participant's glomerular filtration rate (GFR in mL/min) and Carboplatin target area under the concentration (AUC).
Study NCT03953924 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transtheoretical model-based (TTM - based) intervention and motivational interviewing (MI)
Description: The MI was implemented 2 times, 20 minutes each time, the trained nurse interviewed each patient face-to-face by bedside. Based on the evaluation results and motivational interviewing, the change stages of the patients' behavior changes were identified. According to the changing stage,TTM - based intervention was given 3 times in the form of a small course, 20 minutes each time, the key point was divided into three stages.
Study NCT04617249 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: median anesthesia
Description: giving median anesthesia
Study NCT04617249 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: paramedian anesthesia
Description: giving paramedian anesthesia
Study NCT02812095 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Refeeding
Description: when amount of feeding reach to 120mL/kg a day,
Study NCT00371384 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: massage
Description: UP to 10 massages over 10 weeks
Study NCT04411004 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transvaginal ultrasound
Description: Transvaginal ultrasonographic scan to diagnosis the recurrence of rectal endometriosis
Study NCT01261390 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conservative Medical Therapy (CMT)
Description: All participants will meet with a research assistant who will provide 30 minutes of instruction on sleep hygiene and healthy lifestyle guidelines. Each subject's sleep routine will be reviewed with the aim to identify appropriate bed and wake times that provide a consistent schedule and allow for at least 7 hours of time in bed per night. Habits that may impact sleep, such as alcohol consumption, tobacco use, and exercise close to bedtime will be reviewed with appropriate guidance on how to minimize sleep disrupting exposures. Subjects will be provided external nasal dilator strips (Breathe Right®) and advised on how to maximize sleep time in a non-supine position using bed elevation, wedge pillows and/or objects affixed to the back of their night clothes as appropriate.
Study NCT01261390 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Conservative Medical Therapy (CMT)
Description: All participants will meet with a research assistant who will provide 30 minutes of instruction on sleep hygiene and healthy lifestyle guidelines. Each subject's sleep routine will be reviewed with the aim to identify appropriate bed and wake times that provide a consistent schedule and allow for at least 7 hours of time in bed per night. Habits that may impact sleep, such as alcohol consumption, tobacco use, and exercise close to bedtime will be reviewed with appropriate guidance on how to minimize sleep disrupting exposures. Subjects will be provided external nasal dilator strips (Breathe Right®) and advised on how to maximize sleep time in a non-supine position using bed elevation, wedge pillows and/or objects affixed to the back of their night clothes as appropriate.
Study NCT01261390 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Conservative Medical Therapy (CMT)
Description: All participants will meet with a research assistant who will provide 30 minutes of instruction on sleep hygiene and healthy lifestyle guidelines. Each subject's sleep routine will be reviewed with the aim to identify appropriate bed and wake times that provide a consistent schedule and allow for at least 7 hours of time in bed per night. Habits that may impact sleep, such as alcohol consumption, tobacco use, and exercise close to bedtime will be reviewed with appropriate guidance on how to minimize sleep disrupting exposures. Subjects will be provided external nasal dilator strips (Breathe Right®) and advised on how to maximize sleep time in a non-supine position using bed elevation, wedge pillows and/or objects affixed to the back of their night clothes as appropriate.
Study NCT01261390 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham PAP (Sham)
Description: In addition to receiving CMT, participants in this treatment arm will receive a sham PAP unit. Sham devices look like active PAP devices, however, the exhalation port is increased and an orifice-resistor is inserted between the pump and tubing, creating a marginal pressure. A heated humidifier will be provided with this device and PAP masks will be fit and provided following the same procedures as for the active-PAP arms.
Study NCT01261390 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active PAP with RT Support (Active-Beh)
Description: In addition to receiving CMT, participants will receive active-PAP and meet with a PAP-specialist . The CPAP specialist would meet with the participant in person throughout the course of the study (set-up, 1-week, 1-month, 3-month, 6-month, and 9-month). Using the available data from the PAP monitor, the PAP specialist will discuss PAP use, mask leaks, and residual AHI to assist with troubleshooting. Adjustments to equipment would be performed as needed to improve adherence. It is estimated that each in-person follow-up adherence visit with the PAP-specialist would last 30 minutes.
Study NCT01261390 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active PAP with Behavioral Modification (Active+Beh)
Description: In addition to receiving CMT and active-PAP, participants will meet with a behavioral interventionist in addition to PAP-specialist visits. Participants also would speak with the behavioral interventionist over the course of the study (set up, 1-week, 3-week, 1-month, 2-months, 3-months, 5-months and 8-months). The duration of the first 2 behavioral intervention sessions are estimated to be 1-hour long, with subsequent 30-minutes intervention sessions. The intervention will be based on social cognitive theory and feedback concerning adherence with targeted problem solving training.
Study NCT03924388 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidural spinal cord stimulation
Description: The measurements will be obtained in 2 positions of supine and \~ 70° upright adjusted by the tilt-up table.
Study NCT03924388 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trnascutaneous electrical spinal cord stimulation.
Description: The measurements will be obtained in 2 positions of supine and \~ 70° upright adjusted by the tilt-up table.
Study NCT03560453 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project SEARCH Plus ASD Supports
Description: Project SEARCH is an intensive 9-month job training program where youth with developmental disabilities in their last year of high school are embedded in a large community business such as a hospital, government complex, or banking center (Daston et al., 2012). Students with developmental disabilities who participate in this model rotate through three 10-12 week internships within the business where they log approximately 720 hours of internship time learning marketable skills while receiving supported employment. They also get 180 hours of classroom time at the business for a total of approximately 900 hours embedded in the business setting. In addition to these important training components, Project SEARCH requires collaboration between multiple community partners to support students in attaining employment upon completion of the program. Collaborations include students with developmental disabilities and their family, a LEA, a local CRP, the state VR, and a host business.
Study NCT01834456 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Med Complex Children Intervention
Description: Comprehensive Care, including creating a care plan, offering and integrating developmental and behavioral care, with added care coordination in a Medical Home/Primary Care Practice
Study NCT01996111 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Injection of 1.0 cc of 0.9% Saline
Description: Injection of 1.0 cc of 0.9% Saline into affected area
Study NCT01996111 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection of 1.0 cc of 10 mg/ml micrograft dHACM suspension
Description: Injection of 1.0 cc of 10 mg/ml micrograft dHACM suspension into affected area
Study NCT04411004 — intervention group
Intervention type: BEHAVIORAL
Intervention: 5-point Likert scale
Description: Subjective scale to evaluate satisfaction to previous surgical treatment for rectal endometriosis
Study NCT00088933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant fowlpox-CEA(6D)/TRICOM vaccine
Description: Given intradermally
Study NCT01996111 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection of 1.0 cc of 20 mg/ml micrograft dHACM suspension
Description: Injection of 1.0 cc of 20 mg/ml micrograft dHACM suspension into affected area
Study NCT01996111 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection of 1.0 cc of 40 mg/ml micrograft dHACM suspension
Description: Injection of 1.0 cc of 40 mg/ml micrograft dHACM suspension into affected area
Study NCT02162160 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: probiotic creme
Description: Probiotic creme applied
Study NCT02162160 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Creme without probiotics applied in same manner
Study NCT01648062 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Self-Regulation Using Mental Imagery
Description: Comparison of two forms of mental imagery to instigate behaviors that assist in the sleeping process
Study NCT01648062 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sleep Self-Regulation Using Mental Imagery
Description: Comparison of two forms of mental imagery to instigate behaviors that assist in the sleeping process
Study NCT03468725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XPF-008
Description: Capsule filled with XEN1101
Study NCT03468725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Microcrystalline Cellulose
Description: Placebo capsule
Study NCT01492504 — intervention group
Intervention type: DRUG
Intervention: Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)
Description: Observational study - No Intervention \[(subjects were previously treated with Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)\]
Study NCT01951417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene/BPO Gel
Description: Adapalene/Benzoyl Peroxide (BPO) Gel Pump (once daily)
Study NCT00088933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant vaccinia-CEA(6D)-TRICOM vaccine
Description: Given intradermally
Study NCT01951417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moisturizer SPF 30
Description: Moisturizer SPF 30 (once daily)
Study NCT01951417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foam Wash
Description: Foam Wash (twice daily)
Study NCT02794298 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Study NCT02794298 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham-tDCS
Study NCT04220801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZM-H1505R
Description: Single oral doses of 300, 450, 600, 750, and 900 mg of ZM-H1505R or placebo and multiple oral doses of 450, 600, and 750 mg of ZM-H1505R or placebo will be administered in a fasted state, or in the case of Cohort 3 (Part 1), a second dose of 600 mg will be administered in the fed state. During each SAD and MAD dosing period, 2 subjects in each cohort will receive placebo instead of ZM-H1505R. The dose levels may be adjusted based on the safety and tolerability obtained from the previous cohort.
Study NCT00088933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV
Study NCT00088933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given subcutaneously
Study NCT01747499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Study NCT06312800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acamprosate
Description: Randomized allocation of treatments will guide the dispensation of treatments in one of 6 possible sequences--ex, M (methazolamide)- P(placebo)-A (Acamprosate); or PAM or MAP or PMA or AMP or APM. Biostatistician will devise medication randomization strategies and investigators and staff will be blinded.